JP2015504048A - タンパク質分解抵抗性水素結合サロゲートヘリックス - Google Patents

タンパク質分解抵抗性水素結合サロゲートヘリックス Download PDF

Info

Publication number
JP2015504048A
JP2015504048A JP2014548945A JP2014548945A JP2015504048A JP 2015504048 A JP2015504048 A JP 2015504048A JP 2014548945 A JP2014548945 A JP 2014548945A JP 2014548945 A JP2014548945 A JP 2014548945A JP 2015504048 A JP2015504048 A JP 2015504048A
Authority
JP
Japan
Prior art keywords
peptide
amino acid
moiety
formula
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014548945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504048A5 (enExample
Inventor
パラムジット エス． アロラ
パラムジット エス． アロラ
アヌパム パッジーリ
アヌパム パッジーリ
スティーブン ジョイ
スティーブン ジョイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of JP2015504048A publication Critical patent/JP2015504048A/ja
Publication of JP2015504048A5 publication Critical patent/JP2015504048A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014548945A 2011-12-21 2012-12-21 タンパク質分解抵抗性水素結合サロゲートヘリックス Pending JP2015504048A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161578646P 2011-12-21 2011-12-21
US201161578652P 2011-12-21 2011-12-21
US61/578,652 2011-12-21
US61/578,646 2011-12-21
PCT/US2012/071223 WO2013096755A1 (en) 2011-12-21 2012-12-21 Proteolytically resistant hydrogen bond surrogate helices

Publications (2)

Publication Number Publication Date
JP2015504048A true JP2015504048A (ja) 2015-02-05
JP2015504048A5 JP2015504048A5 (enExample) 2016-02-18

Family

ID=48669532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548945A Pending JP2015504048A (ja) 2011-12-21 2012-12-21 タンパク質分解抵抗性水素結合サロゲートヘリックス

Country Status (6)

Country Link
US (1) US9376469B2 (enExample)
EP (1) EP2793920A4 (enExample)
JP (1) JP2015504048A (enExample)
CN (1) CN104066435A (enExample)
CA (1) CA2895930A1 (enExample)
WO (1) WO2013096755A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515613A (ja) * 2014-04-04 2018-06-14 デル マー ファーマシューティカルズ、インコーポレイテッド 癌を治療するための白金含有抗腫瘍剤とジアンヒドロガラクチトールの類縁体又は誘導体の組み合わせ
JP2024124545A (ja) * 2020-04-30 2024-09-12 国立大学法人東北大学 蛍光偏光免疫分析法および蛍光標識物質

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033645A1 (en) * 2011-08-31 2013-03-07 New York University Thioether-,ether-, and alkylamine-linked hydrogen bond surrogate pertidomimentics
US20140205681A1 (en) * 2013-01-19 2014-07-24 New York University HYDROGEN-BOND SURROGATE PEPTIDES AND PEPTIDOMIMETICS FOR p53 REACTIVATION
US20150065436A1 (en) * 2013-09-03 2015-03-05 University Of Southern California INHIBITING INTERACTION BETWEEN HIF-1ALPHA AND p300/CBP WITH HYDROGEN BOND SURROGATE-BASED HELICES
WO2015127342A1 (en) * 2014-02-22 2015-08-27 New York University Alpha3beta hydrogen bond surrogate macrocycles as modulators of ras
CN108024987A (zh) * 2014-10-10 2018-05-11 德玛医药 用于治疗癌症的二去水卫矛醇的类似物或衍生物与含铂抗肿瘤药物的组合
WO2019038344A1 (en) * 2017-08-23 2019-02-28 Cyca Oncosolutions Limited CELL MEMBRANE PENETRATION CONJUGATES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118620A2 (en) * 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
WO2010033879A2 (en) * 2008-09-18 2010-03-25 New York University Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682174C (en) * 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
EP2334697A1 (en) * 2008-09-22 2011-06-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8835602B2 (en) * 2009-03-06 2014-09-16 Indian Institute Of Science Templates for nucleation and propagation of peptide secondary structure
EP2473182B1 (en) * 2009-09-03 2014-07-16 Gradalis, Inc. Targeted delivery using tissue-specific peptidomimetic ligands
CA2828889A1 (en) * 2011-03-04 2012-09-13 New York University Hydrogen bond surrogate macrocycles as modulators of ras
WO2013033645A1 (en) * 2011-08-31 2013-03-07 New York University Thioether-,ether-, and alkylamine-linked hydrogen bond surrogate pertidomimentics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118620A2 (en) * 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
WO2010033879A2 (en) * 2008-09-18 2010-03-25 New York University Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMBIOCHEM, vol. 11, no. 15, JPN6016036881, 2010, pages 2104 - 2107, ISSN: 0003406095 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515613A (ja) * 2014-04-04 2018-06-14 デル マー ファーマシューティカルズ、インコーポレイテッド 癌を治療するための白金含有抗腫瘍剤とジアンヒドロガラクチトールの類縁体又は誘導体の組み合わせ
US11541027B2 (en) 2014-04-04 2023-01-03 Del Mar Pharmaceuticals (Bc) Ltd. Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases
JP2024124545A (ja) * 2020-04-30 2024-09-12 国立大学法人東北大学 蛍光偏光免疫分析法および蛍光標識物質

Also Published As

Publication number Publication date
US9376469B2 (en) 2016-06-28
WO2013096755A1 (en) 2013-06-27
EP2793920A1 (en) 2014-10-29
US20130210144A1 (en) 2013-08-15
CN104066435A (zh) 2014-09-24
EP2793920A4 (en) 2015-07-01
CA2895930A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
JP2015504048A (ja) タンパク質分解抵抗性水素結合サロゲートヘリックス
Buckton et al. Cyclic peptides as drugs for intracellular targets: the next frontier in peptide therapeutic development
JP7232533B2 (ja) Ｒａｓ抑制性ペプチドおよびその使用
Yoo et al. Macropinocytosis as a key determinant of peptidomimetic uptake in cancer cells
US20130123196A1 (en) Thioether-, ether-, and alkylamine-linked hydrogen bond surrogate peptidomimetics
Panzeri et al. Cyclic isoDGR and RGD peptidomimetics containing bifunctional diketopiperazine scaffolds are integrin antagonists
Huber et al. Structure-based optimization and characterization of macrocyclic zika virus NS2B-NS3 protease inhibitors
Hameed et al. Enhanced Delivery of Synthetic Labelled Ubiquitin into Live Cells by Using Next‐Generation Ub–TAT Conjugates
WO2019094830A1 (en) Mitofusin modulation agents and methods of use thereof
Ruiz-Santaquiteria et al. Trypanothione reductase inhibition and anti-leishmanial activity of all-hydrocarbon stapled α-helical peptides with improved proteolytic stability
Wallbrecher et al. A critical assessment of the synthesis and biological activity of p53/human double minute 2‐stapled peptide inhibitors
Gomez‐Paloma et al. Design and synthesis of cyclopeptide analogues of the potent histone deacetylase inhibitor FR235222
de Rezende et al. A Review of the Synthetic Strategies for the Development of BODIPY Dyes for Conjugation with Proteins.
KR20240082377A (ko) 펩티드
KR20240111739A (ko) 새로운 vash 억제제, 이의 접합체 및 이의 약물 또는 연구 도구로서의 용도
Lee et al. Converting polar cyclic peptides into membrane permeable molecules using N‐methylation
Qvit et al. Synthesis of a novel macrocyclic library: discovery of an IGF-1R inhibitor
Sacco et al. RGD Cyclopeptide Equipped with a Lysine‐Engaging Salicylaldehyde Showing Enhanced Integrin Affinity and Cell Detachment Potency
Fernández et al. Synthetic peptides derived from an N‐terminal domain of the E2 protein of GB virus C in the study of GBV‐C/HIV‐1 co‐infection
Van der Poorten et al. Indoloazepinone‐Constrained Oligomers as Cell‐Penetrating and Blood–Brain‐Barrier‐Permeating Compounds
Xu et al. A Template‐assembled Model of the N‐peptide Helix Bundle from HIV‐1 Gp‐41 with High Affinity for C‐peptide
CN114450399A (zh) 用于治疗癌症的乳酸脱氢酶抑制剂多肽
EP4501941A1 (en) Peptide complex having trkb binding activity
Wang Developing Functional Peptides as Synthetic Receptors, Binders of Protein and Probes for Bacteria Detection
Li et al. Macrocyclic Peptides Containing an Imidazopyridinium (IP+) Unit Display Enhanced Passive Cell Permeability

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170522